NImmune Biopharma, a late-clinical-stage biopharmaceutical company specializing in precision inflammation and immunology (I&I) therapeutics, has announced the acquisition of development and commercialization rights to omilancor across several Asian markets, including China, Hong Kong, Taiwan, South Korea, and others. This transaction enables NImmune to fully own the global rights to omilancor, a once-daily oral therapy currently in Phase 3 clinical trials for ulcerative colitis (UC) and Phase 2 trials for Crohn’s disease (CD). With regulatory approval for Phase 3 trials in multiple regions, NImmune is positioned to accelerate the development of omilancor globally.
The acquisition follows the wind-down of LianBio, which provided NImmune with the opportunity to consolidate global rights for omilancor. Dr. Josep Bassaganya-Riera, NImmune’s Founder & CEO, emphasized the significance of this development, stating that the transaction aligns with the company’s ongoing global Phase 3 program for omilancor in UC. He highlighted the company’s focus on securing strategic partnerships to further expedite the Phase 3 timelines and address unmet needs in inflammatory bowel disease (IBD) treatments worldwide.
Omilancor targets the LANCL2 pathway, modulating immune and metabolic signals in the gut to create an anti-inflammatory environment, reduce harmful immune responses, and promote regulatory T cell function. In a Phase 2 trial, omilancor showed a significant clinical remission rate of 30.4% in UC patients, with no identified treatment-related adverse events. NImmune is also developing a companion biomarker to optimize treatment response, leveraging its TITAN-X platform for precision medicine.
With this acquisition, NImmune aims to bring omilancor’s best-in-class potential to millions of IBD patients in the U.S. and globally, further strengthening its position in the field of immunoregulatory therapies.
About NImmune Biopharma
NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from NImmune’s discovery platform is omilancor, a wholly owned oral, once-daily, gut-restricted, first-in-class therapeutic currently in Phase 3 clinical development, which targets LANCL2 for ulcerative colitis and Crohn’s disease. Published, final and complete Phase 2 proof-of-concept data for omilancor show potential best-in-class efficacy and safety.
